SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Oct. 13, 2025 — Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology firm dedicated to developing innovative cancer treatments, today revealed its plan to deliver an oral presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, scheduled for October 22-26, 2025, in Boston, MA.
The particulars of the presentation are as follows:
Abstract title: Unveiling AN4035: A novel CEACAM5-targeting antibody-drug conjugate (ADC) equipped with a proprietary pan-RAS(ON) inhibitor payload, engineered to expand the therapeutic window
Date and Time: Saturday, October 25, 2025; 11:45 AM – 12:15 PM ET
Session Title: Spotlight on Proffered Papers 3: Novel Therapeutic Agents
Location: Level 3, Ballroom AB, Hynes Convention Center, Boston, MA
The Company will release an additional press statement detailing the scientific rationale and key data highlights for AN4035 once the abstract is publicly available on the AACR portal on October 22, 2025.
About Adlai Nortye
Adlai Nortye (NASDAQ: ANL) is a global clinical-stage entity focused on creating advanced cancer therapies, maintaining global R&D centers in the U.S. and China. We are advancing a pipeline of innovative drug candidates across two primary therapeutic domains: next-generation PD-1/L1 modulation, which includes AN8025, a multi-functional fusion protein designed to modulate both T cells and antigen-presenting cells, and AN4005, a first-in-class oral small-molecule PD-L1 inhibitor; and RAS-targeted therapies, comprising AN9025, an oral pan-RAS(ON) inhibitor with the potential to address various RAS-driven cancers, and AN4035, an innovative CEACAM5-targeting antibody-drug conjugate armed with a potent pan-RAS(ON) inhibitor payload.
Forward-Looking Statement
This announcement contains forward-looking statements. These disclosures are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements can be identified by terms such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “potential,” “continue,” “ongoing,” “targets,” and similar expressions. Among other things, statements that are not historical facts, including those concerning the Company’s beliefs and expectations, the business outlook, management quotations within this announcement, and the Company’s strategic and operational plans, are or incorporate forward-looking statements.
The Company may also issue written or oral forward-looking statements in its periodic reports submitted to the U.S. Securities and Exchange Commission (the “SEC”), in press releases and other written materials, and in verbal communications by its officers, directors, or employees to third parties. Forward-looking statements inherently involve risks and uncertainties. Factors that could cause the Company’s actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: the initiation, timing, progress, and outcomes of the Company’s preclinical studies, clinical trials, and other therapeutic candidate development efforts; the Company’s capacity to advance its therapeutic candidates into clinical trials or to successfully complete its preclinical studies or clinical trials; whether clinical trial results will be predictive of real-world outcomes; the Company’s receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory submissions and clearances; the clinical development, commercialization, and market acceptance of the Company’s therapeutic candidates; the Company’s ability to establish, manage, and sustain corporate collaborations, as well as the ability of its collaborators to execute on their development and commercialization plans; the implementation of the Company’s business model and strategic plans for its business and therapeutic candidates; the scope of protection the Company can establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to conduct its business without infringing the intellectual property rights of others; estimates of the Company’s expenses, future revenues, capital requirements, and its need for and ability to access sufficient additional financing; risks related to changes in healthcare laws, rules, and regulations in the PRC and United States or elsewhere. Further details regarding these and other risks are included in the Company’s SEC filings. All information provided in this announcement and in the attachments is current as of the date of this announcement, and the Company assumes no obligation to update any forward-looking statement, except as mandated by applicable law.
Company contact:
Investor Relations
Email:
